5-Amino-1MQ vs Amlexanox
Research Verdict
Amlexanox is the stronger research reference for the stated comparison criteria. 5-Amino-1MQ: mouse-only data from a single research group targeting NNMT inhibition; no human trials.
Quick Answers
Which is better, 5-Amino-1MQ or Amlexanox?
Amlexanox is the stronger research reference for the stated comparison criteria. 5-Amino-1MQ: mouse-only data from a single research group targeting NNMT inhibition; no human trials.
What is the key difference between 5-Amino-1MQ and Amlexanox?
5-Amino-1MQ inhibits NNMT (nicotinamide N-methyltransferase) to increase NAD+ and energy expenditure; amlexanox inhibits IKKe/TBK1 to reduce inflammatory metabolic signaling - completely different enzyme targets with no mechanistic overlap.
Evidence Comparison
5-Amino-1MQ: mouse-only data from a single research group targeting NNMT inhibition; no human trials. Amlexanox: one small human pilot study (Reilly et al. 2015, Cell Metab, n=42) showing modest metabolic improvements via IKKe/TBK1 inhibition. Amlexanox has marginally stronger evidence by virtue of having any human data at all.
Evidence Context Favoring 5-Amino-1MQ
NNMT-specific metabolic research where the NAD+/energy expenditure pathway is the focus, accepting animal-only evidence.
Evidence Context Favoring Amlexanox
Research requiring at least some human pilot data, or studies focused on inflammatory metabolic signaling via IKKe/TBK1.
Side-by-Side Snapshot
| Evidence grade | 5-Amino-1MQ: Level D Amlexanox: Level C |
|---|---|
| Research status | 5-Amino-1MQ: Preclinical Amlexanox: Phase 2 |
| Primary category | 5-Amino-1MQ: Weight Loss & Metabolic Amlexanox: Weight Loss & Metabolic |
| Cited studies | 5-Amino-1MQ: 2 Amlexanox: 2 |